As of 2017 no drug was approved to treat<unk> s. Drugs that inhibit interleukin 1 activity have been the preferred treatment since they emerged in 2005; since 2012 a consensus guideline has recommended treatment with anakinra. Immunosuppressant drugs such as corticosteroids, cyclooxygenase inhibitors, interferon alpha may be effective. In June 2018 NHS England published a Clinical Commissioning Policy: Anakinra to treat periodic fevers and autoinflammatory disorders (all ages) which stated that "Anakinra may be used as a first line treatment in patients with a documented diagnosis of<unk> ". Because anakinra is so highly and rapidly effective for inducing complete remission of<unk> , it has been suggested that in patients who do not respond to anakinra, the diagnosis should be reconsidered. Anakinra is not curative, however; symptoms recur soon after treatment stops.
Schnitzler syndrome
Bloom syndrome
Plummer–Vinson syndrome
Senter syndrome
Tropical sprue
Hartnup disease
Food protein-induced enterocolitis syndrome
Juvenile polyposis syndrome